Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 35Genitourinary 11Breast 11Classical hematology 9Thoracic 8Plasma cell 8Myeloid 7Gynecologic 6Tumor-Agnostic 4Head & Neck 3Dermatologic 3Sarcoma 2CNS 2Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Other 1Lymphoid 1

Conditions

Melanoma 3

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Aspirin × Dermatologic × Clear all
NCT03396952 2022-10-13

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

University of California, San Francisco

Phase 2 Completed
27 enrolled 13 charts
Dermatologic

Melanoma

NCT04062032 2022-02-18

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
41 enrolled
Dermatologic

Melanoma

NCT04066725 2022-02-18

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
95 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡